Insmed’s Promising Growth Prospects and Strong Pipeline Justify Buy Rating
Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Insmed (INSM – Research Report) yesterday and set a price target ...
Insmed’s Promising Financial Performance and Pipeline Developments Lead to Buy Rating
Analyst Jeffrey Hung from Morgan Stanley maintained a Buy rating on Insmed (INSM – Research Report) and keeping the price target at $85.00.Stay ...